Taylor A.Goodspeed

Associate

ニューヨーク + 1.212.326.3450

Taylor Goodspeed focuses on regulatory, compliance, and civil litigation matters involving the health care industry. She counsels and defends hospitals, health systems, life science companies, and other health care entities in civil fraud and abuse investigations and litigation, particularly under the civil False Claims Act (FCA) and similar state laws. She helps steer clients through high-profile investigations from federal and state agencies.

Taylor also counsels corporations on mitigating human trafficking-related risks in corporate supply chains and implementing appropriate compliance training and employee policies and procedures on these topics. She conducts internal investigations and responds to governmental investigations involving human trafficking, and her practice extends to human trafficking-related litigation brought pursuant to the Trafficking Victims Protection Reauthorization Act (TVPRA). She has presented on issues of human trafficking in corporate supply chains, including in the health care and real estate industries.

Taylor also worked closely with the in-house legal team at a global biopharmaceutical company while on secondment in its litigation and government investigations group. During that time, she managed a wide variety of matters including civil litigation, interactions with enforcement authorities, and internal investigations across the globe.

Taylor maintains an active pro bono practice in the anti-trafficking space, serving on Jones Day's Anti-Human Trafficking Committee and on the American Hospital Association's (AHA) Human Trafficking Advisory Council. She also frequently presents on the Firm's pro bono anti-trafficking efforts.

Taylor served two terms as a member of the Women's Leadership Council for the American Health Law Association (AHLA).

担当案件

  • Large regional medical practice obtains declination from Department of Justice in Stark Law and False Claims Act matterJones Day represented a large regional medical provider in a False Claims Act investigation conducted by the Department of Justice and Eastern District of Pennsylvania regarding alleged upcoding, medical necessity and Stark Law violations.
  • Celgene wins complete defense verdict in case filed by health insurer, Humana Inc., relating to off-label use of cancer medicationsOn March 2, 2023, Jones Day prevailed in a five-week jury trial on behalf of Celgene Corporation in a lawsuit brought by health insurance company Humana, Inc.
  • Nurx merges with Thirty MadisonJones Day provided healthcare and data privacy counsel to Nurx in connection with its merger with Thirty Madison, a leading digital healthcare company operating across the U.S.
  • Maven Clinic receives historic Series D investment fundingJones Day advised Maven Clinic as health regulatory counsel in its $110 million Series D investment round, co-led by Dragoneer Investment Group and Lux Capital.
  • MDLIVE sells company to Cigna's EvernorthJones Day advised MDLIVE in its sale to Cigna's health services subsidiary Evernorth.
  • Digital health companies, specialty hospitals, and health systems maintain compliance with multistate requirements through 50-state surveyJones Day is representing digital health companies, specialty hospitals, and health systems in maintaining compliance with multistate requirements through a regularly updated, extensive 50-state survey on state laws and regulations applicable to telehealth activities of physicians and other health care professionals including licensing, establishing patient relationships, provider-to-provider consulting, supervision and delegation among providers, and prescribing and treatment standards.
  • Several digital health companies successfully close state regulatory board investigationsJones Day successfully represented several digital health companies and their affiliated physicians in responding to state medical board investigations regarding the provision of clinical services including certain laboratory tests and prescription drug orders.
  • Academic medical center considers multi-state second opinion servicesJones Day provided strategic health regulatory guidance to a preeminent academic medical center in connection with their multi-state second opinion and telehealth programs.
  • Innovative primary care clinic expands platform and offeringsJones Day is providing on-going strategic regulatory guidance and advice to a membership-based primary care practice in connection with telemedicine, COVID-19 response, and general health care regulatory and compliance matters.
  • Digital health company expands telehealth programming in response to the COVID-19 public health crisisJones Day represented a digital health company in the expansion of their telehealth programming in response to the COVID-19 public health crisis.
  • Emerging specialty service launches telehealth platformJones Day advised an emerging direct to consumer telehealth organization focusing on teledermatology with terms of service, privacy policy, and telehealth consent for launching operations in several states across the U.S.
  • National digital health company launches government partnershipJones Day advised a large digital health company with multi-clinical services in negotiating a partnership with a state government program to provide telehealth and telemedicine consults during the COVID-19 state of emergency.
  • Durable medical equipment company defends against False Claims Act qui tam lawsuitJones Day is representing a durable medical equipment company in connection with a False Claims Act investigation alleging violation of state best price requirements.
  • Hospital system defends against novel federal and state False Claims Act qui tam lawsuitsJones Day is representing a hospital system in connection with two novel federal and state False Claims Act matters alleging improper arrangements with Medicaid managed health care plans.
  • Large digital health company grows operations across U.S.Jones Day advised a large digital health company in expanding operations throughout multiple states in the U.S. and in responding to several state regulator inquiries regarding its operations.